Hedner U - Search Results

1

Joint disease, the hallmark of haemophilia: what issues and challenges remain despite the development of effective therapies?

Lambert T, Auerswald G, Benson G, Hedner U, Jiménez-Yuste V, Ljung R, Morfini M, Remor E, Santagostino E, Zupančić Šalek S. Lambert T, et al. Among authors: hedner u. Thromb Res. 2014 Jun;133(6):967-71. doi: 10.1016/j.thromres.2014.02.015. Epub 2014 Feb 21. Thromb Res. 2014. PMID: 24613700 Review.

2

Joint protection in haemophilia.

Rodriguez-Merchan EC, Jimenez-Yuste V, Aznar JA, Hedner U, Knobe K, Lee CA, Ljung R, Querol F, Santagostino E, Valentino LA, Caffarini A. Rodriguez-Merchan EC, et al. Among authors: hedner u. Haemophilia. 2011 Sep;17 Suppl 2:1-23. doi: 10.1111/j.1365-2516.2011.02615.x. Haemophilia. 2011. PMID: 21819491 Review.

3

Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?

Rodriguez-Merchan EC, Hedner U, Heijnen L, Jimenez-Yuste V, Lee CA, Morfini M, Querol F, Roosendaal G, Santagostino E, Solimeno LP. Rodriguez-Merchan EC, et al. Among authors: hedner u. Haemophilia. 2008 Nov;14 Suppl 6:68-81. doi: 10.1111/j.1365-2516.2008.01892.x. Haemophilia. 2008. PMID: 19134036

4

Correlation between different intensities of anti-vitamin K treatment and coagulation parameters.

Jerkeman A, Astermark J, Hedner U, Lethagen S, Olsson CG, Berntorp E. Jerkeman A, et al. Among authors: hedner u. Thromb Res. 2000 Jun 15;98(6):467-71. doi: 10.1016/s0049-3848(00)00203-6. Thromb Res. 2000. PMID: 10899345

5

Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis.

Holst J, Lindblad B, Wedeberg E, Bergqvist D, Nordfang O, Ostergaard PB, Hedner U. Holst J, et al. Among authors: hedner u. Thromb Res. 1993 Dec 1;72(5):467-70. doi: 10.1016/0049-3848(93)90248-m. Thromb Res. 1993. PMID: 8303690 No abstract available.

6

Influence of a low molecular weight heparin on the inhibition of factor Xa and thrombin in hip surgery.

Mätzsch T, Bergqvist D, Fredin H, Hedner U, Ostergaard P. Mätzsch T, et al. Among authors: hedner u. Thromb Res. 1989 Nov 15;56(4):559-64. doi: 10.1016/0049-3848(89)90241-7. Thromb Res. 1989. PMID: 2558424 No abstract available.

7

The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.

Holst J, Lindblad B, Bergqvist D, Hedner U, Nordfang O, Ostergaard P. Holst J, et al. Among authors: hedner u. Thromb Res. 1997 May 15;86(4):343-8. doi: 10.1016/s0049-3848(97)00078-9. Thromb Res. 1997. PMID: 9187023 Clinical Trial.

8

Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.

Hedner U. Hedner U. Thromb Haemost. 1999 Aug;82(2):531-9. Thromb Haemost. 1999. PMID: 10605747 Review. No abstract available.

9

Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000.

Hedner U. Hedner U. Semin Thromb Hemost. 2000;26(4):363-6. doi: 10.1055/s-2000-8453. Semin Thromb Hemost. 2000. PMID: 11092209 Review.

10

Mechanism of action of factor VIIa in the treatment of coagulopathies.

Hedner U. Hedner U. Semin Thromb Hemost. 2006 Apr;32 Suppl 1:77-85. doi: 10.1055/s-2006-939557. Semin Thromb Hemost. 2006. PMID: 16673269 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

279 results

Search Page